Avidity Biosciences
RNA
#3287
Rank
S$4.29 B
Marketcap
$35.75
Share price
-5.44%
Change (1 day)
-0.43%
Change (1 year)

P/E ratio for Avidity Biosciences (RNA)

P/E ratio as of April 2025 (TTM): -8.65

According to Avidity Biosciences's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -8.64677. At the end of 2022 the company had a P/E ratio of -6.66.

P/E ratio history for Avidity Biosciences from 2020 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-6.662.6%
2021-6.49-44.86%
2020-11.8

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-5.07-41.33%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.0676-99.22%๐Ÿ‡บ๐Ÿ‡ธ USA
-7.27-15.87%๐Ÿ‡บ๐Ÿ‡ธ USA
21.3-346.44%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.3229-96.27%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
12.5-244.52%๐Ÿ‡บ๐Ÿ‡ธ USA
10.5-221.46%๐Ÿ‡ฌ๐Ÿ‡ง UK

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.